Association between time spent with residual viremia after achievement of virological suppression and type of first-line antiretroviral regimen

Association between time spent with residual viremia after achievement of virological suppression and type of first-line antiretroviral regimen

Bibliographic Details
Main Authors:	A. Lazzarin, L. Galli, N. Galizzi, A. Castagna, N. Gianotti, M. Ripa, A. Andolina, S. Nozza, V. Spagnuolo, A. Poli
Format:	Article
Language:	English
Published:	Elsevier 2017-12-01
Series:	Journal of Virus Eradication
Online Access:	http://www.sciencedirect.com/science/article/pii/S205566402030618X

Similar Items

Durability of switch regimens based on rilpivirine or on integrase inhibitors, both in association with tenofovir and emtricitabine, in HIV-infected, virologically suppressed patients
by: Nicola Gianotti, et al.
Published: (2017-11-01)

Efficacy and safety of switching from branded to generic antiretrovirals in virologically suppressed HIV-infected patients.
by: Nicola Gianotti, et al.
Published: (2017-01-01)

A nucleoside-sparing regimen of dolutegravir plus ritonavir-boosted atazanavir in HIV-1-infected patients with virological failure: the DOLATAV study
by: Spagnuolo V, et al.
Published: (2019-01-01)

Cells producing residual viremia during antiretroviral treatment appear to contribute to rebound viremia following interruption of treatment.
by: Hadega A Aamer, et al.
Published: (2020-08-01)

Low-Level Viremia Predicts Virological Failure in HIV-Infected Omani Patients Receiving Antiretroviral Therapy
by: Zied Gaifer MBBS, MD, et al.
Published: (2020-12-01)

Virological failure and all-cause mortality in HIV-positive adults with low-level viremia during antiretroviral treatment.
by: Olof Elvstam, et al.
Published: (2017-01-01)

Cost analysis of initial highly active antiretroviral therapy regimens for managing human immunodeficiency virus-infected patients according to clinical practice in a hospital setting
by: Colombo GL, et al.
Published: (2013-12-01)

Investigating the risk factors associated with low-level viremia and virological failure in HIV-1 infected children undergoing antiretroviral therapy
by: Gupta, Shivani
Published: (2017)

Dolutegravir: Virologic response and tolerability of initial antiretroviral regimens for adults living with HIV.
by: Analú Correa, et al.
Published: (2020-01-01)

Immunological and virological characterization of HIV-1 viremia controllers in the North Region of Brazil
by: Samara Tatielle M. Gomes, et al.
Published: (2017-06-01)

Virological and immunological efficacy of metabolically favorable antiretroviral therapy regimens in HIV patients who had no previous treatment
by: E. I. Veselova, et al.
Published: (2020-06-01)

Persistent HIV-1 Viremia on Antiretroviral Therapy: Measurement and Mechanisms
by: Jana L. Jacobs, et al.
Published: (2019-10-01)

Antiretroviral treatment switch strategies for lowering the costs of antiretroviral therapy in subjects with suppressed HIV-1 viremia in Spain
by: Llibre JM, et al.
Published: (2013-05-01)

Factors associated with high-risk low-level viremia leading to virologic failure: 16-year retrospective study of a Chinese antiretroviral therapy cohort
by: Tong Zhang, et al.
Published: (2020-02-01)

Impact of chemotherapy for HIV-1 related lymphoma on residual viremia and cellular HIV-1 DNA in patients on suppressive antiretroviral therapy.
by: Anthony R Cillo, et al.
Published: (2014-01-01)

Residual Viremia in Treated HIV+ Individuals.
by: Jessica M Conway, et al.
Published: (2016-01-01)

Virological suppression and clinical management in response to viremia in South African HIV treatment program: A multicenter cohort study.
by: Lucas E Hermans, et al.
Published: (2020-02-01)

HIV-1 residual viremia correlates with persistent T-cell activation in poor immunological responders to combination antiretroviral therapy.
by: Maud Mavigner, et al.
Published: (2009-10-01)

Virologic suppression in patients with a documented M184V/I mutation based on the number of active agents in the antiretroviral regimen
by: Mallory T Mouradjian, et al.
Published: (2020-09-01)

Modern antiretroviral regimens
by: A. V. Kravchenko
Published: (2016-12-01)

The dual-target approach in viral HIV-1 viremia testing: An added value to virological monitoring?
by: Alessandra Amendola, et al.
Published: (2020-01-01)

Association of residual plasma viremia and intima-media thickness in antiretroviral-treated patients with controlled human immunodeficiency virus infection.
by: Anders Boyd, et al.
Published: (2014-01-01)

Rebound of residual plasma viremia after initial decrease following addition of intravenous immunoglobulin to effective antiretroviral treatment of HIV
by: Sandberg Johan K, et al.
Published: (2011-06-01)

Long-term efficacy and safety of rilpivirine plus abacavir and lamivudine in HIV-1 infected patients with undetectable viral load.
by: Nadia Galizzi, et al.
Published: (2018-01-01)

The effect of raltegravir intensification on low-level residual viremia in HIV-infected patients on antiretroviral therapy: a randomized controlled trial.
by: Rajesh T Gandhi, et al.
Published: (2010-08-01)

HIV-1 genotypic drug resistance in patients with virological failure to single-tablet antiretroviral regimens in southern Taiwan
by: Tsai HC, et al.
Published: (2018-08-01)

P16-48. Immunologic and virologic characterization of an ART-treated HIV-1 patients cohort with long-term control of viremia
by: Harari A, et al.
Published: (2009-10-01)

Residual viremia is preceding viral blips and persistent low-level viremia in treated HIV-1 patients.
by: Laura Marije Hofstra, et al.
Published: (2014-01-01)

Hepatitis B viremia in HIV-coinfected individuals under antiretroviral therapy
by: Leonardo Weissmann, et al.
Published: (2019-11-01)

Correction: The dual-target approach in viral HIV-1 viremia testing: An added value to virological monitoring?
by: Alessandra Amendola, et al.
Published: (2020-01-01)

Antiretroviral intensification and valproic acid lack sustained effect on residual HIV-1 viremia or resting CD4+ cell infection.
by: Nancie M Archin, et al.
Published: (2010-02-01)

Residual Viremia Is Linked to a Specific Immune Activation Profile in HIV-1-Infected Adults Under Efficient Antiretroviral Therapy
by: Mehwish Younas, et al.
Published: (2021-03-01)

Monitoring the virological response to antiretroviral therapy in Africa
by: John, Laurence Michael
Published: (2007)

Correction: The Effect of Raltegravir Intensification on Low-level Residual Viremia in HIV-Infected Patients on Antiretroviral Therapy: A Randomized Controlled Trial.
by: Rajesh T. Gandhi, et al.
Published: (2011-08-01)

Budget impact analysis of antiretroviral less drug regimen simplification in HIV-positive patients on the Italian National Health Service
by: Restelli U, et al.
Published: (2014-09-01)

Pregnancy and virologic response to antiretroviral therapy in South Africa.
by: Daniel Westreich, et al.
Published: (2011-01-01)

Kinetics and Determining Factors of the Virologic Response to Antiretrovirals during Pregnancy
by: Adriana Weinberg, et al.
Published: (2009-01-01)

Factors associated with virological suppression to antiretroviral therapy among people living with HIV
by: Hui-ChenChu, et al.
Published: (2014)

Clinical and virological factors associated with viremia in pandemic influenza A/H1N1/2009 virus infection.
by: Herman Tse, et al.
Published: (2011-01-01)

NNRTI-associated mutations in patients with virologic failure on first-line regimen in Yekaterinburg
by: A. Chuykov, et al.
Published: (2014-04-01)

Cannot write session to /tmp/vufind_sessions/sess_n26cbkb7hf1ou6du1ll69p2iu7